Skip to content
DataLookout
Menu

NCT07912710

China HEalthy Aging and Dementia Study (HEAD)

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Mild cognitive impairment (MCI)
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Dementia
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Mild cognitive impairment due to Alzheimer's disease (MCI due to AD)
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Dementia due to Alzheimer's disease (AD dementia)
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Mini-Mental State Examination (MMSE) total score
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Montreal Cognitive Assessment (MoCA) total score
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score
Timeframe: Baseline and approximately annual follow-up assessments (up to 50 years)

Secondary (27)

Auditory Verbal Learning Test (AVLT) learning score
Auditory Verbal Learning Test (AVLT) short-delay recall score
Auditory Verbal Learning Test (AVLT) long-delay recall score
Forward Digit Span Test score
Backward Digit Span Test score
Show 22 moreShow less
Trail Making Test Part A (TMT-A) completion time
Trail Making Test Part B (TMT-B) completion time
Clock Drawing Test (CDT) total score
Verbal Fluency Test (VFT) total score
Plasma amyloid-β 1-42 (Aβ1-42) concentration
Plasma amyloid-β 1-40 (Aβ1-40) concentration
Plasma amyloid-β 1-42/1-40 ratio (Aβ1-42/Aβ1-40)
Plasma phosphorylated tau 181 (p-tau181) concentration
Plasma phosphorylated tau 217 (p-tau217) concentration
Plasma total tau (t-tau) concentration
Plasma neurofilament light chain (NfL) concentration
Plasma glial fibrillary acidic protein (GFAP) concentration
Cerebrospinal fluid amyloid-β 1-42 (Aβ1-42) concentration
Cerebrospinal fluid amyloid-β 1-40 (Aβ1-40) concentration
Cerebrospinal fluid amyloid-β 1-42/1-40 ratio (Aβ1-42/Aβ1-40)
Cerebrospinal fluid phosphorylated tau 181 (p-tau181) concentration
Cerebrospinal fluid phosphorylated tau 217 (p-tau217) concentration
Cerebrospinal fluid total tau (t-tau) concentration
Cerebrospinal fluid neurofilament light chain (NfL) concentration
Cerebrospinal fluid glial fibrillary acidic protein (GFAP) concentration
Regional brain atrophy assessed by structural MRI
Cerebral amyloid-β burden assessed by PET

Arms and interventions

China HEAD Community Cohort

A nationwide, multicenter, community-based prospective cohort of individuals aged 50-79 years from eastern, northern, southern, western, and central regions of China, established using standardized protocols to ensure harmonized data collection and quality control across participating centers.

China HEAD Familial Sub-cohort

A nationwide, multicenter prospective sub-cohort of individuals aged 18 years or older with a family history of Alzheimer's disease, established using standardized protocols to ensure harmonized data collection and quality control across participating centers.

Sites

30 sites in 1 country